Drug‐induced QT interval prolongation: regulatory perspectives and drug development

References

• Keating MT, Sanguinetti MC. Molecular and cellular mech-anisms of cardiac arrhythmias. Cell 2001;104:569–80.
   Google Scholar
• Shah RR. Drug-induced prolongation of the QT interval: regulatory dilemmas and implications for approval and label-ling of a new chemical entity. Fundam Clin Pharmacol 2002; 16:147–56.
   Google Scholar
• Fung MC, Hsiao-hui Wu H, Kwong K, Hornbuckle K, Muniz E. Evaluation of the profile of patients with QTc prolongation in spontaneous adverse event reporting over the past three decades-1969-1998. Pharmacoepidemiol and Drug Safety 2000;9 (Suppl 1):524–5.
   Google Scholar
• Salle P, Rey JL, Bernasconi P, Quiret JC, Lombaert M. (Torsades de pointes. Apropos of 60 cases). [French]. Ann Cardiol Angeiol (Paris) 1985;34: 381–8.
   Google Scholar
• Milon D, Daubert JC, Saint-Marc C, Gouffault J. (Torsade de pointes. Apropos of 54 cases). [French]. Ann Fr Anesth Reanim 1982;1: 513–20.
   Google Scholar
• Shah RR. The significance of QT interval in drug develop-ment. Br J Clin Pharmacol 2002;54:188–202.
   Google Scholar
• Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993; 270:2590–7.
   Google Scholar
• Rodriguez I, Kilborn MJ, Liu XK, Pezzullo JC, Woosley RL. Drug-induced QT prolongation in women during the men-strual cycle. JAMA 2001;285:1322–6.
   Google Scholar
• Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med 1996;335:290–1.
   Google Scholar
• Wysowski DK, Corken A, Gallo-Torres H, Talarico L, Rodriguez EM. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol 2001;96:1698–703.
   Google Scholar
• Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993; 269: 1532–6.
   Google Scholar
• Charbit B, Becquemont L, Lepere B, Peytavin G, Funck-Brentano C. Pharmacokinetic and pharmacodynamic inter-action between grapefruit juice and halofantrine. Clin Pharmacol Ther 2002;72:514–23.
   Google Scholar
• Roe CM, Odell KW, Henderson RR. Concomitant use of antipsychotics and drugs that may prolong the QT interval. J Clin Psychopharmacol 2003;23:197–200.
   Google Scholar
• Curtis LH, Ostbye T, Sendersky V, Hutchison S, Allen LaPointe NM, Al-Khatib SM, et al. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med 2003;114:135–41.
   Google Scholar
• Shah RR. Pharmacogenetic aspects of drug-induced torsade de pointes: Potential tool for improving clinical drug develop-ment and prescribing. Drug Saf 2004: (in press).
   Google Scholar
• Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long-QT syndrome: clinical impact. Circulation 1999;99:529–33.
   Google Scholar
• Shah RR. Withdrawal of terodiline: A tale of two toxicities. In: Mann RD, Andrews LB eds. Pharmacovigilance. London: John Wiley & Sons Ltd; 2002:135–54.
   Google Scholar
• Yang P, Kanki H, Drolet B, Yang T, Wei J, Viswanathan PC, et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 2002; 105: 1943–8.
   Google Scholar
• Webster R, Allan G, Anto-Awuakye K, Harrison A, Kidd T, Leishman D, et al. Pharmacokinetic/pharmacodynamic as-sessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog. Xenobiotica 2001;31: 633–50.
   Google Scholar
• Ben-David J, Zipes DP. Alpha-adrenoceptor stimulation and blockade modulates cesium-induced early afterdepolariza-tions and ventricular tachyarrhythmias in dogs. Circulation 1990;82:225–33.
   Google Scholar
• Furushima H, Chinushi M, Washizuka T, Aizawa Y. Role of a1-blockade in congenital long QT syndrome-Investigation by exercise stress test. Jpn Circ J 2001;65:654–8.
   Google Scholar
• Fulop G, Phillips RA, Shapiro AK, Gomes JA, Shapiro E, Nordlie JW. ECG changes during haloperidol and pimozide treatment of Tourette's disorder. Am J Psychiatry 1987;144: 673–5.
   Google Scholar
• Volperian VR, Zhou Z, Mohammad S, Hoon TJ, Studenik C, January CT. Torsade de pointes with an antihistamine metabolite: potassium channel blockade with desmethylaste-mizole. J Am Coll Cardiol 1996;28:1556–61.
   Google Scholar
• Billon N, Funck-Brentano C, Cohen A, Chauvel C, Le Liboux A, Jaillon P. Influence of CYP2D6 genetic polymorphism on the pharmacokinetics and pharmacodynamic effects of ter-ikalant, a new K+ channel blocker. Fundam Clin Pharmacol 1995;9:88.
   Google Scholar
• Maginn M, Frederiksen K, Adamantidis MM, Bischoff U, Matz J. The effects of sertindole and its metabolites on cardiac ion channels and action potentials. J Physiol 2000;525:79P.
   Google Scholar
• Hartigan-Go K, Bateman DN, Nyberg G, Martensson E, Thomas SH. Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Clin Pharmacol Ther 1996;60:543–53.
   Google Scholar
• Thanaccody R, Daly AK, Thomas SH. Influence of CYP2D6 genotype on the QTc interval and plasma concentrations of thioridazine and its metabolites in psychiatric patients taking chronic therapy. Clin Pharmacol Ther 2003;73: 77.
   Google Scholar
• Hartigan-Go K, Bateman ND, Daly AK, Thomas SH. Stereoselective cardiotoxic effects of terodiline. Clin Pharma-col Ther 1996;60:89–98.
   Google Scholar
• Bayer R, Schwarzmaler J, Pernice R. Basic mechanism underlying prenylamine-induced torsade de pointes: differ-ences between prenylamine and fendiline due to basic actions of the isomers. Curr Med Res Opin 1988;11:254–72.
   Google Scholar
• Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003;58:32–45.
   Google Scholar
• Sponer G. Prolongation of repolarization in pre-clinical investigations and phase I/II clinical trials: what should be done? Eur Heart J 2001;3 (Suppl K):K101–4.
   Google Scholar
• De Ponti F, Poluzzi E, Cavalli A, Recanatini M, Montanaro N. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Saf 2002;25:263–86.
   Google Scholar
• Jaillon P, Morganroth J, Brumpt I, Talbot G. The Sparfloxacin Safety Group. Overview of electrocardiographic and cardio-vascular safety data for sparfloxacin. J Antimicrob Chemo-therap 1996;37 (Supp A):161–7.
   Google Scholar
• Smalley W, Shatin D, Wysowski DK, Gurwitz J, Andrade SE, Goodman M, et al. Contraindicated use of cisapride: impact of Food and Drug Administration regulatory action. JAMA 2000;284:3036–9.
   Google Scholar
• Krasucki C, McFarlane F. Electrocardiograms, high-dose antipsychotic treatment and College guidelines. Psychiatric Bull 1996;20:326–30.
   Google Scholar